Early evidence of population impact of RSV vaccination on hospitalisations among older adults in Scotland
- Type
- Report
- Published
- 14 February 2025
- Conditions and diseases
- Immunisations
Description
Public Health Scotland has carried out work looking at the early impact of the respiratory syncytial virus (RSV) vaccine in those aged 75 to 79 years old.
Using a regression discontinuity design (RDD) analysis, we were able to show that age groups eligible for vaccine had a significantly reduced rate of hospitalisation compared to those who were not eligible, showing an early indication of the effect of the vaccine.
Findings from this report were published in Lancet Infectious Diseases in February 2025.
This publication is not licensed for re-use under the Open Government Licence v3.0.
Files
Media enquiries
If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.
Requesting other formats and reporting issues
If you require publications or documents in other formats, please email phs.otherformats@phs.scot.
To report any issues with a publication, please email phs.generalpublications@phs.scot.